Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049628 | 0.81 | ALDH1A1 (0.68) | PLATKDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4520864 | 0.80 | ALDH1A1 (0.57) | PLATKDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4054217 | 0.80 | ALDH1A1 (0.60) | PLATKDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4052148 | 0.77 | ALDH1A1 (0.57) | PLATKDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4229511 | 0.77 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL4047424 | 0.77 | HPGD (0.65) | PLATKDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4223039 | 0.76 | ALDH1A1 (0.56) | PLATKDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4214432 | 0.76 | PARP1 (0.55) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL4047628 | 0.76 | KDM4E (0.57) | PLATKDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4052993 | 0.75 | ALDH1A1 (0.60) | PLATKDM4EALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | claimed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | claimed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | claimed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PLAT 361/4885KDM4E 515/4885ALDH1A1 282/4885 |
| US-20080015182-A1 | Potent PARP Inhibitors | PARP1, PARP2, PARP3 | PLAT 361/4885KDM4E 515/4885ALDH1A1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.